Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus IPI-549 versus nivolumab alone in immune therapy-naive advanced urothelial carcinoma
2019-000854-69Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Nivolumab plus IPI-549 with Nivolumab monotherapy (2 arms). Primary endpoint: Objective response rate in patients with baseline mMDSC >=22.3%. Started Jun 2019; status: completed.
02
Drugs
nivolumabeganelisib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2019-000854-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000854-69.